Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654641 | 0.86 | SKP2 (0.52) | CA2CA1CA9CA5ASKP2 | |
| SCHEMBL24415722 | 0.84 | CA2 (0.53) | CA2CA1CA9CA5AALDH1A1 | |
| SCHEMBL8118864 | 0.81 | CA2 (0.50) | CA2CA1CA9CA5AKIF11 | |
| SCHEMBL3590286 | 0.79 | CA1 (0.49) | CA2CA1CA9CA5ATSHR | |
| SCHEMBL12158313 | 0.78 | SKP2 (0.44) | CA2CA1CA9CA5ASKP2 | |
| SCHEMBL3217315 | 0.76 | CA2 (0.49) | CA2CA1CA9CA5AKIF11 | |
| SCHEMBL9027014 | 0.75 | SKP2 (0.57) | SKP2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL841783 | 0.74 | SKP2 (0.73) | SKP2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL31079561 | 0.74 | SKP2 (0.61) | SKP2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL31634603 | 0.74 | SKP2 (0.73) | SKP2ALDH1A1CYP3A4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | disclosed |
| EP-1885722-B1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK CANADA INC (CA) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262430-A1 | NOVEL ANTIBODIES | ELLIS JONATHAN HENRY | 2011-10-27 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-8013159-B2 | Quinoline derivatives as EP4 antagonists | MERCK CANADA INC. (CA) | 2011-09-06 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | MERCK CANADA INC. (CA) | 2009-04-16 | — | — | US | disclosed |
| EP-1885722-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122403-A1 | QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099226-A1 | Quinoline derivatives as ep4 antagonists | PTGER4, PTGER1, PTGER3 | CA2 1459/4885CA1 2636/4885CA9 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.